We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search

Clear all

Refine your search

Content type

Tags

Firm name

Author

Language

824 results found

Article

Rothwell, Figg, Ernst & Manbeck, PC | USA | 18 Mar 2019

Jury Finds Amgen Antibody Patents Not Invalid

Over four years ago, in October 2014, Amgen initiated a patent infringement suit against Sanofi and Regeneron regarding biologics for treatment of

Article

Rothwell, Figg, Ernst & Manbeck, PC | USA | 27 Feb 2019

The Third Time is the Charm for Sanofi in its IPR Challenge of Immunex’s ʼ487 Patent

On February 14, 2019, the PTAB issued final written decisions in two separate IPRs filed by Sanofi-Aventis, Genzyme Corp., and Regeneron

Article

Finnegan, Henderson, Farabow, Garrett & Dunner LLP | USA | 19 Feb 2019

The Plight of U.S. Pat. No. 8,679,487 at PTAB; if Two Arrows Miss the Mark, Launch a Third

Sanofi-Aventis U.S., LLC et al. V. Immunex Corp., IPR2017-01884 and IPR2017-01879 (P.T.A.B. Feb. 14, 2019) (HULSE, Moore, Obermann); see also denial

Article

Jenner & Block LLP | USA | 17 Sep 2018

French Pharmaceutical Company Sanofi Agrees to Pay More Than $25 Million for FCPA Violations

On September 4, 2018, the French pharmaceutical company Sanofi S.A. (Sanofi) agreed to pay the US Securities and Exchange Commission (SEC) more than

Article

FB Rice | USA | 29 May 2018

The challenge in obtaining broad antibody genus claims in the US

Functionally defined genus claims are vulnerable to invalidity based on lack of written description support, particularly where it is difficult to

Article

Rothwell, Figg, Ernst & Manbeck, PC | USA | 3 Apr 2018

Global Approvals for Insulin Glargine Promise a More Affordable, Long-Acting Treatment for Diabetes

Last week, Mylan N.V. and Biocon Ltd. announced that their jointly-developed insulin glargine biosimilar, Semglee, received marketing approval from

Article

Buckley LLP | USA | 14 Mar 2018

Sanofi announces DOJ declination in FCPA investigation

As previously covered, French pharmaceutical company Sanofi S.A. announced in October 2014 that it was investigating whether certain payments made by

Article

Barker Brettell LLP | USA | 7 Mar 2018

A Blow to Broad Antibody-to-Target Claims - The USPTO Follows Amgen Inc. v. Sanofi (Fed. Cir. 2017) and Issues New Guidance

Upon discovery of a novel biological target, for example in a newly characterised pathway, it is fairly common to attempt to patent protect an

Article

Rothwell, Figg, Ernst & Manbeck, PC | USA | 19 Oct 2017

Sanofi Files Suit Against Merck Sharp & Dohme Over Second NDA for Insulin Glargine Biologic: A Look at the Differences in Biosimilar Approval Pathways

On August 8, 2017, Sanofi-Aventis (“Sanofi”) filed a patent infringement suit in the United States District Court for the District of New Jersey

Article

Osler Hoskin & Harcourt LLP | Canada | 31 Aug 2017

Corporate whistleblower rewarded pursuant to the False Claims Act

Sanofi-Aventis has been rewarded $38.7 million for its role as a whistleblower in a settlement between another major pharmaceutical company and the

Previous page 1 2 3 ...